This study investigates a drug called Pegozafermin to see if it can safely treat people with compensated cirrhosis caused by MASH. Researchers will evaluate its effect on liver health and related symptoms.
Eligibility:
• Ages 18–75
• Diagnosed with MASH and biopsy-confirmed compensated cirrhosis (fibrosis stage F4)